Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus UROPLUS DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus UROPLUS DS.
GANTRISIN vs UROPLUS DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
UROPLUS DS is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim inhibits dihydrofolate reductase, blocking the reduction of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade disrupts folic acid synthesis, leading to bacterial growth inhibition.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
UROPLUS DS (methenamine mandelate 1 g + sodium acid phosphate 500 mg) oral: 1 tablet twice daily.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 11-13 hours in adults with normal renal function; prolonged to 16-20 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 25 hours in severe impairment (CrCl <30 mL/min).
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal excretion of unchanged drug accounts for approximately 40-50% of elimination; hepatic metabolism (primarily via CYP3A4) and subsequent biliary/fecal excretion constitute the remainder with about 20-30% recovered in feces as metabolites.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic